[Lisocabtagene maraleucel (DLBCL, HGBL, PMBCL and FL3B, second line) – Addendum to Commission A23-48]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005387
German
Original Title:
Lisocabtagen maraleucel (DLBCL, HGBL, PMBCL und FL3B, Zweitlinie) - Addendum zum Projekt A23-48 (Dossierbewertung)
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a23-98.html
Year Published:
2023
URL for published report:
https://www.iqwig.de/download/a23-98_lisocabtagen-maraleucel_addendum-zum-projekt-a23-48_v1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Antigens, CD19
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
Keywords
- Lisocabtagene maraleucel
- Lymphoma – B-Cell
- Lymphoma – Large B-Cell – Diffuse
- Lymphoma – Follicular
- Benefit Assessment
- NCT03575351
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.